{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:11:41Z","timestamp":1792606301598,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of the study was to investigate the risk of human papillomavirus (HPV) genotyping particularly vaccine genotypes and multiple infections for cervical precancer and cancer, which might contribute to developing genotype-specific screening strategy and assessing potential effects of HPV vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The HPV genotypes were identified using the Seq HPV assay on self-collected samples. Hierarchical ranking of each genotype was performed according to positive predictive value (PPV) for cervical intraepithelial neoplasia 2\/3 or worse (CIN2+\/CIN3+). Multivariate logistic regression model was used to estimate the odds ratios (ORs) with 95% confidence interval (CI) of CIN2+ according to multiplicity of types and vaccine types.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2811 HPV-positive women were analyzed. The five dominant HPV genotypes in high-grade lesions were 16\/58\/52\/33\/18. The overall ranking orders were HPV16\/33\/35\/58\/31\/68\/18\/ 56\/52\/66\/51\/59\/45\/39 for CIN2+ and HPV16\/33\/31\/58\/45\/66\/52\/18\/35\/56\/51\/68\/59\/39 for CIN3+. The risks of single infection versus co-infections with other types lower in the hierarchy having CIN2+ were not statistically significant for HPV16 (multiple infection vs. single infection: OR\u2009=\u20090.8, 95%CI\u2009=\u20090.6-1.1, <jats:italic>P<\/jats:italic>\u2009=\u20090.144) or other genotypes (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.0036) after conservative Bonferroni correction. Whether HPV16 was present or not, the risks of single infection versus multiple infection with any number (2, \u22652, or\u2009\u2265\u20093) of types for CIN2+ were not significantly different. In addition, HPV31\/33\/45\/52\/58 covered by nonavalent vaccine added 27.5% of CIN2, 23.0% of CIN3, and 12.5% of cancer to the HPV16\/18 genotyping. These genotype-groups were at significantly higher risks than genotypes not covered by nonavalent vaccine. Moreover, genotypes covered by nonavalent vaccine contributed to 85.2% of CIN2 lesions, 97.9% of CIN3 and 93.8% of cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Partial extended genotyping such as HPV33\/31\/58 but not multiplicity of HPV infections could serve as a promising triage for HPV-positive self-samples. Moreover, incidence rates of cervical cancer and precancer were substantial attributable to HPV genotypes covered by current nonavalent vaccination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09126-3","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:05:14Z","timestamp":1641470714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination"],"prefix":"10.1186","volume":"22","author":[{"given":"Fangbin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisha","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"issue":"6","key":"9126_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"9126_CR2","unstructured":"WHO. A cervical cancer-free future: First-ever global commitment to eliminate a cancer Https:\/\/www.Who.Int\/News\/Item\/17-11-2020-A-Cervical-Cancer-Free-Future-First-Ever-Global-Commitment-To-Eliminate-A-Cancer."},{"issue":"1","key":"9126_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"J Walboomers","year":"1999","unstructured":"Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139.","journal-title":"J Pathol"},{"issue":"5","key":"9126_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/jnci\/djq562","volume":"103","author":"M Schiffman","year":"2011","unstructured":"Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"9126_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/jnci\/djq356","volume":"102","author":"SK Kjaer","year":"2010","unstructured":"Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"9126_CR6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1055-9965.EPI-19-0239","volume":"28","author":"R Adcock","year":"2019","unstructured":"Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. Role of HPV genotype, multiple infections and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomark Prev. 2019;28(11):1816\u201324.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"9126_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"9126_CR8","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.7150\/jca.48357","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Du H, Xiao A, Wang C, Huang X, Liu Z, et al. Type-specific distribution of cervical hrHPV infection and the association with cytological and histological results in a large population-based cervical Cancer screening program: baseline and 3-year longitudinal data. J Cancer. 2020;11(20):6157\u201367.","journal-title":"J Cancer"},{"issue":"12","key":"9126_CR9","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1111\/cas.14212","volume":"110","author":"K Matsumoto","year":"2019","unstructured":"Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M, et al. Reduction in HPV16\/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. Cancer Sci. 2019;110(12):3811\u201320.","journal-title":"Cancer Sci"},{"issue":"7","key":"9126_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/infdis\/jiq139","volume":"203","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Katki HA, Hildesheim A, Rodr\u00edguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203(7):910\u201320.","journal-title":"J Infect Dis"},{"issue":"2","key":"9126_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ijc.31326","volume":"143","author":"A Del Mistro","year":"2018","unstructured":"Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. Int J Cancer. 2018;143(2):333\u201342.","journal-title":"Int J Cancer"},{"key":"9126_CR12","doi-asserted-by":"crossref","unstructured":"Nyg\u00e5rd M, Hansen B, Kjaer S, Hortlund M, Tryggvad\u00f3ttir L, Munk C, et al. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. Hum Vaccin Immunotherapeutics. 2021;17(4):972\u201381.","DOI":"10.1080\/21645515.2020.1814097"},{"issue":"1","key":"9126_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","volume":"137","author":"J Monsonego","year":"2015","unstructured":"Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015;137(1):47\u201354.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"9126_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2014.03.552","volume":"133","author":"EL Dickson","year":"2014","unstructured":"Dickson EL, Vogel RI, Geller MA, Downs LS. Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31-65. Gynecol Oncol. 2014;133(3):405\u20138.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"9126_CR15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1128\/JCM.00087-13","volume":"51","author":"M Schmitt","year":"2013","unstructured":"Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, et al. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol. 2013;51(5):1458\u201364.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"9126_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2019.10.003","volume":"155","author":"P Wu","year":"2019","unstructured":"Wu P, Xiong H, Yang M, Li L, Wu P, Lazare C, et al. Co-infections of HPV16\/18 with other high-risk HPV types and the risk of cervical carcinogenesis: a large population-based study. Gynecol Oncol. 2019;155(3):436\u201343.","journal-title":"Gynecol Oncol"},{"issue":"10108","key":"9126_CR17","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","volume":"390","author":"WK Huh","year":"2017","unstructured":"Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143\u201359.","journal-title":"Lancet"},{"issue":"2","key":"9126_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","volume":"20","author":"NJ Polman","year":"2019","unstructured":"Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229\u201338.","journal-title":"Lancet Oncol"},{"issue":"3","key":"9126_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ygyno.2014.01.006","volume":"132","author":"JL Belinson","year":"2014","unstructured":"Belinson JL, Wang G, Qu X, Du H, Shen J, Xu J, et al. The development and evaluation of a community based model for cervical cancer screening based on self-sampling. Gynecol Oncol. 2014;132(3):636\u201342.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"9126_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/LGT.0000000000000577","volume":"25","author":"H Du","year":"2021","unstructured":"Du H, Duan X, Liu Y, Shi B, Zhang W, Wang C, et al. Evaluation of Cobas HPV and SeqHPV assays in the Chinese multicenter screening trial. J Low Genit Tract Dis. 2021;25(1):22\u20136.","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"9126_CR21","doi-asserted-by":"publisher","first-page":"e0234518","DOI":"10.1371\/journal.pone.0234518","volume":"15","author":"F Song","year":"2020","unstructured":"Song F, Du H, Wang C, Huang X, Wu R. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples. PLoS One. 2020;15(6):e0234518.","journal-title":"PLoS One"},{"key":"9126_CR22","doi-asserted-by":"crossref","unstructured":"Song F, Belinson JL, Yan P, Huang X, Wang C, Hui D, et al. Wu R: Evaluation of p16INK4a immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China. Gynecol Oncol. 2021;162(2):322\u201330.","DOI":"10.1016\/j.ygyno.2021.05.014"},{"issue":"1","key":"9126_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12879-021-06109-4","volume":"21","author":"F Song","year":"2021","unstructured":"Song F, Yan P, Huang X, Wang C, Qu X, Du H, et al. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16(INK4a) immunostaining in China. BMC Infect Dis. 2021;21(1):400.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"9126_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1309\/AJCP9P2KJSXEKCJB","volume":"141","author":"X Yi","year":"2014","unstructured":"Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, et al. Development and validation of a new HPV genotyping assay based on next-generation sequencing. Am J Clin Pathol. 2014;141(6):796\u2013804.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"9126_CR25","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/LGT.0000000000000239","volume":"20","author":"JL Belinson","year":"2016","unstructured":"Belinson JL, Pretorius RG. A standard protocol for the colposcopy exam. J Low Genit Tract Dis. 2016;20(4):e61\u20132.","journal-title":"J Low Genit Tract Dis"},{"issue":"10","key":"9126_CR26","doi-asserted-by":"publisher","first-page":"djv185","DOI":"10.1093\/jnci\/djv185","volume":"107","author":"K Sundstrom","year":"2015","unstructured":"Sundstrom K, Ploner A, Arnheim-Dahlstrom L, Eloranta S, Palmgren J, Adami HO, et al. Interactions between high- and low-risk HPV types reduce the risk of squamous cervical Cancer. J Natl Cancer Inst. 2015;107(10):djv185.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"9126_CR27","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/ijc.32919","volume":"146","author":"R Venetianer","year":"2020","unstructured":"Venetianer R, Clarke MA, van der Marel J, Tota J, Schiffman M, Dunn ST, et al. Identification of HPV genotypes causing cervical pre-Cancer using tissue-based genotyping. Int J Cancer. 2020;146(10):2836\u201344.","journal-title":"Int J Cancer"},{"issue":"40","key":"9126_CR28","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1016\/j.vaccine.2020.07.036","volume":"38","author":"A Cornall","year":"2020","unstructured":"Cornall A, Brotherton J, Callegari E, Tan F, Saville M, Pyman J, et al. Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard. Vaccine. 2020;38(40):6312\u20139.","journal-title":"Vaccine"},{"issue":"2","key":"9126_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1006\/gyno.2001.6370","volume":"83","author":"J Belinson","year":"2001","unstructured":"Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province cervical Cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83(2):439\u201344.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"9126_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/LGT.0000000000000530","volume":"24","author":"M Demarco","year":"2020","unstructured":"Demarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, et al. A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis. 2020;24(2):144\u20137.","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"9126_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcv.2014.02.002","volume":"60","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, et al. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol. 2014;60(1):44\u20139.","journal-title":"J Clin Virol"},{"issue":"4","key":"9126_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.21147\/j.issn.1000-9604.2019.04.10","volume":"31","author":"S Zhao","year":"2019","unstructured":"Zhao S, Zhao X, Hu S, Lu J, Duan X, Zhang X, et al. Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China. Chin J Cancer Res. 2019;31(4):663\u201372.","journal-title":"Chin J Cancer Res"},{"issue":"11","key":"9126_CR33","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S Sanjose","year":"2010","unstructured":"Sanjose S. Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix a: human papillomavirus genotype attribution in invasive cervical cancer a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"9","key":"9126_CR34","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1002\/ijc.32669","volume":"146","author":"MH Stoler","year":"2019","unstructured":"Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, et al. Approaches to triage optimization in HPV primary screening: extended genotyping and p16\/Ki-67 dual-stained cytology - retrospective insights from ATHENA. Int J Cancer. 2019;146(9):2599\u2013607.","journal-title":"Int J Cancer"},{"issue":"4","key":"9126_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ijc.31261","volume":"143","author":"K Cuschieri","year":"2018","unstructured":"Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018;143(4):735\u201345.","journal-title":"Int J Cancer"},{"issue":"4","key":"9126_CR36","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.3802\/jgo.2019.30.e52","volume":"30","author":"KA So","year":"2019","unstructured":"So KA, Lee IH, Lee KH, Hong SR, Kim YJ, Seo HH, et al. Human papillomavirus genotype-specifc risk in cervical carcinogenesis. J Gynecol Oncol. 2019;30(4):e52.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"9126_CR37","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.3802\/jgo.2017.28.e30","volume":"28","author":"XL Zhao","year":"2017","unstructured":"Zhao XL, Hu SY, Zhang Q, Dong L, Feng RM, Han R, et al. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. J Gynecol Oncol. 2017;28(4):e30.","journal-title":"J Gynecol Oncol"},{"issue":"11","key":"9126_CR38","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1086\/428850","volume":"191","author":"R Herrero","year":"2005","unstructured":"Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1796\u2013807.","journal-title":"J Infect Dis"},{"issue":"9","key":"9126_CR39","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/ijc.24528","volume":"125","author":"N Wentzensen","year":"2009","unstructured":"Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125(9):2151\u20138.","journal-title":"Int J Cancer"},{"issue":"4","key":"9126_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/LGT.0000000000000487","volume":"23","author":"AD Iacobone","year":"2019","unstructured":"Iacobone AD, Bottari F, Radice D, Preti EP, Franchi D, Vidal Urbinati AM, et al. Distribution of high-risk human papillomavirus genotypes and multiple infections in Preneoplastic and neoplastic cervical lesions of unvaccinated women. J Low Genit Tract Dis. 2019;23(4):259\u201364.","journal-title":"J Low Genit Tract Dis"},{"key":"9126_CR41","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m K, Dillner J. How many human papillomavirus types do we need to screen for? J Infect Dis. 2021;223(9):1510\u201311.","DOI":"10.1093\/infdis\/jiaa587"},{"issue":"1","key":"9126_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-9378-7-38","volume":"7","author":"B Serrano","year":"2012","unstructured":"Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.","journal-title":"Infect Agent Cancer"},{"issue":"14","key":"9126_CR43","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei J, Ploner A, Elfstr\u00f6m K, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical Cancer. N Engl J Med. 2020;383(14):1340\u20138.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09126-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:05:52Z","timestamp":1641470752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9126"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09126-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of Peking University Shenzhen Hospital (PUSH, No.2018035). The study protocol was conformed to the Declaration of Helsinki, and the digital informed consent was approved by the Institutional Ethics Committee of PUSH (No. 2018035) and local institutions based on the prior approval from Institutional Ethics Committee of BGI-Shenzhen for the digital informed consent form and its signature manner. Digital informed consent was obtained from all participants including consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Digital informed consent was obtained from all participants including consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}